Survival with frontline abiraterone higher for African American vs White men with mCRPCJanuary 11th 2022
This real-world cohort study corroborates prior research showing a greater clinical benefit for abiraterone acetate in African American versus White patients with metastatic castration-resistant prostate cancer.
Enrollment completed for phase 3 trial of cabozantinib plus atezolizumab in renal cell carcinomaJanuary 5th 2022
The phase 3 CONTACT-03 trial is specifically accruing patients with inoperable, locally advanced or metastatic renal cell carcinoma with disease progression after receiving an immune checkpoint inhibitor as the immediate prior therapy.
Urinary incontinence linked to increased risk of falling in older adultsDecember 17th 2021
“Falls are the leading cause of accidental death in seniors, and many people don’t know that having bladder control problems makes you about twice as likely to fall over,” said William Gibson, MBChB, MRCP, PhD.
Trial of novel PSMA-PET imaging agent in prostate cancer hits enrollment milestoneDecember 9th 2021
The PROPELLER trial is exploring the novel PSMA-PET imaging product 64Cu-SAR-bisPSMA in patients with treatment-naïve, histologically confirmed prostate cancer who are scheduled for radical prostatectomy.
Study identifies optimal extent of PLND by risk status with radical prostatectomyDecember 2nd 2021
"We sought to conduct a National Cancer Database analysis evaluating the impact of the extent of lymphadenectomy on survival outcomes for patients presenting with intermediate- and high-risk prostate cancer,” said Furkan Dursun, MD.